Anemia in chronic kidney disease: Clinical implications of early management

Dialysis and Transplantation

Volumn 32, Issue 4, 2003, Pages 179-187+222

  Kliger, Alan S ^a   Padilla, Norma ^b  

^a YALE UNIVERSITY   (United States)

^b Scientific Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CLINICAL MEDICINE; CLINICAL TRIAL; COGNITION; DIALYSIS; DISEASE COURSE; ENERGY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; PATHOGENESIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037383329     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. National Institutes of Health Consensus Development Conference. National Institutes of Health: Morbidity and Mortality of Dialysis. NIH Consensus Statement, 1993.
2. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999; 10:1281-1286.
3. U.S. Renal Data System. USRDS 1997 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997.
4. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465-2473.
5. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610-619.
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28:53-61.
7. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10:1793-1800.
8. Kazmi WH, Kausz AT, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am d Kidney Dis 2001; 38:803-812.
9. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4:979-987.
10. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6:1-4.
11. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321:158-163.
12. Wizemann V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64:202-206.
13. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function [see comments]. Am J Kidney Dis 1999; 33:1122-1130.
14. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 1991; 35:280-287.
15. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32:S133-S141.
16. Jeren-Struji'c B, Raos V, Jeren T, Horvatin-Godler S. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (rHuEPO). Angiology 2000; 51:131-139.
17. Massimetti C, Pontillo D, Feriozzi S, Costantini S, Capezzuto A, Ancarani E. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 1998; 16:317-324.
18. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-S238.
19. Besarab A, Levin A. Defining a renal anemia management period. Am J Kidney Dis 2000; 36(Suppl 3):S13-S23.
20. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 1979; 54:877-884.
21. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001; 60:1875-1884.
22. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11:239-245.
23. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125-134.
24. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347-354.
25. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54:1720-1725.
26. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: Focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15(Suppl 3):14-18.
27. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.
28. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
29. Radermacher J, Koch KM. Treatment of renal anemia by erythropoietin substitution: The effects on the cardiovascular system. Clin Nephrol 1995; 44(Suppl 1):S56-S60.
30. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35:250-256.
31. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29:541-548.
32. Teehan BP. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18:50-59.
33. Schwartz AB, Prior JE, Mintz GS, Kim KE, Kahn SB. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin. Transplant Proc 1991; 23:1827-1830.
34. Eckardt KU. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999; 14:1317-1323.
35. St Peter WL, Xue J, Ebben J, Collins AJ. Pre-end-stage renal disease erythropoietin use predicts hospitalization in the periods before and after end-stage renal disease diagnosis [abstract A1274]. San Francisco: ASN/ISN World Congress of Nephrology, 2001.
36. Xue JL, Ebben JP, St Peter WL, Constantini EG, Collins AJ. Correction of anemia with erythropoietin during the two-year pre-ESRD period: Post-ESRD mortality [abstract A1327]. San Francisco: ASN/ISN World Congress of Nephrology, 2001.
37. St Peter WL, Xue JL, Ebben JP, Collins AJ. Pre-ESRD erythropoietin use predicts Medicare expenditures in the periods before and after end-stage renal disease diagnosis [abstract A1272]. San Francisco: ASN/ISN World Congress of Nephrology, 2001.
38. Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61:21-25.
39. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts: Blood transfusion. N Engl J Med 1999; 340:438-447.
40. Muirhead N. Erythropoietin and renal transplantation. Kidney Int 1999; 69(Suppl):S86-S92.
41. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13:2027-2032.
42. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001; 12:2759-2767.